Clinical Trial

AMT-116 in Combination With AK112 in Patients With Lung Cancer

Recruiting Phase 1/2
View on ClinicalTrials.gov →
Summary
The purpose of this study is to evaluate the safety and efficacy of AMT-116 in combination with Ivonescimab (AK112) in patients with advanced non-small cell lung cancer (NSCLC). The study is divided into two parts: the part I is dose escalation and the Part Ⅱ for expansion.
Protocol Amendment History 1 change
critical Recruitment opened 2026-07-15
Trial Details
NCT Number NCT07590531
Lead Sponsor Multitude Therapeutics Inc.
Conditions Advanced Non-small Cell Lung Cancer (NSCLC)
Enrollment 118 participants
Start Date 2026-06-29
Primary Completion 2027-05-30 (estimated)
Study Completion 2027-12-31 (estimated)
Updated on ClinicalTrials.gov 2026-08-10